Agenus Reports 51% of Patients Survive at Least 18 Months in BOT+BAL Colorectal Cancer Trial

• Agenus reported durable survival with botensilimab and balstilimab in refractory colorectal cancer in Phase 1b findings already presented at SITC 2026.
• The study involved heavily pretreated patients with microsatellite-stable metastatic disease without active liver metastases; some long-term survivors remained off all cancer treatment.
• Long-term survival was not limited to favorable clinical profiles; fewer prior treatments were associated with better survival outcomes.
• The findings support earlier treatment evaluation, including the Phase 3 ROBBIN strategy testing the combination before surgery in high-risk colon cancer.
• No treatment-related deaths occurred; immune-mediated diarrhea or colitis resolved in nearly all affected long-term survivors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611060900BIZWIRE_USPR_____20261106_BW518994) on November 06, 2026, and is solely responsible for the information contained therein.